Actavis asks court to let it stop manufacturing older Alzheimer's treatment

Actavis ($ACT) has made its case to a federal appeals court that it should be able to stop making the original version of its Alzheimer's treatment Namenda IR, which is going off patent, and replace it with its once-daily version Namenda XR, Reuters reports. Actavis had made the decision last year to stop manufacturing it as a way to get patients to switch to the newer version. The New York Attorney General sued the company over the ploy, which it called monopolistic. A lawyer for Actavis told the court it will lose about $200 million in sales if it cannot discontinue the older drug. Actavis has been ordered to manufacture both while it sorts the matter out in court. Story | More

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Vaccine maker Inovio has accused a longtime manufacturing partner of hampering its efforts to produce 1 million doses of a potential COVID-19 vaccine.

Roche's global manufacturing leader Pierre-Alain Ruffieux will take the reins and oversee the Moderna COVID-19 vaccine collaboration.